Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMA901 with GM-CSF in Advanced Renal Cell Carcinoma
NCT00523159Phase 2Completed
- Sponsor
- Immatics
- Start
- May 2007
- Primary completion
- Aug 2009
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of IMA901 in renal cell carcinoma (RCC) (2 arms), sponsored by Immatics. Primary endpoint: Disease Control Rate at 26 weeks. Started May 2007; status: completed.
02
Drugs
IMA901
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00523159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00523159.